摘要 : Objective:To study the effect of Herceptin combined with Phryl on serum tumor markers and toxicities in patients with breast cancer.Methods:A total of 66 patients with breast cancer admitted from February 2019 to February 2020 wer... 展开 Objective:To study the effect of Herceptin combined with Phryl on serum tumor markers and toxicities in patients with breast cancer.Methods:A total of 66 patients with breast cancer admitted from February 2019 to February 2020 were selected as the research objects.They were divided into two groups by random number table method,with 33 cases in each group.The control group was treated with Herceptin,and the observation group was treated with Fray on the basis of the control group.The levels of serum tumor markers[cancer antigen 15-3(CA15-3),cell protein 19(CYFRA21-1)]and toxic reactions were compared between the two groups before treatment and 4 weeks after treatment.Results:After 4 weeks of treatment,serum CA15-3 and CYFRA21-1 in both groups were lower than before treatment,and those in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).There was significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusion:Herceptin combined with Flux in the treatment of breast cancer patients can reduce the level of serum tumor markers,inhibit tumor growth,and reduce the risk of toxicity. 收起